We need your support to keep TheyWorkForYou running and make sure people across the UK can continue to hold their elected representatives to account.Donate to our crowdfunder
To ask Her Majesty's Government, further to the Written Answer by Earl Howe on 5 December (WA 114-15), whether the proposed clinical trial at Moorfields Eye Hospital will also employ retinal pigmented epithelial (RPE) cells generated by direct reprogramming of other adult cell types, described by Sir Ian Wilmut as avoiding risks of tumorigenesis associated with a pluripotent stage; and whether the RPE cells to be used in the trial or the embryonic cells from which they were derived have been regularly tested to ensure that they do not also exhibit chromosomal alterations in culture.
The product to be used in the clinical trial at Moorfields Eye Hospital does not employ retinal pigmented epithelial cells generated by direct reprogramming of other adult cell types.
Testing is undertaken to ensure that chromosomal alterations during culture do not occur.
Details of these tests are commercially confidential and therefore we are unable to reveal them.